

---

---

**UNITED STATES  
SECURITIES AND EXCHANGE COMMISSION**  
Washington, D.C. 20549

---

**FORM 8-K**

---

**CURRENT REPORT**  
Pursuant to Section 13 or 15(d)  
of the Securities Exchange Act of 1934

**Date of Report (Date of earliest event reported): September 18, 2017**

---

**ONCOMED PHARMACEUTICALS, INC.**

(Exact name of registrant as specified in its charter)

---

**Delaware**  
(State or other jurisdiction  
of incorporation)

**001-35993**  
(Commission  
File Number)

**38-3572512**  
(IRS Employer  
Identification Number)

**800 Chesapeake Drive**  
**Redwood City, California 94063**  
(Address of principal executive offices, including Zip Code)

**Registrant's telephone number, including area code: (650) 995-8200**

---

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

- Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

---

---

---

**Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.**

On September 18, 2017, Paul J. Hastings, the Chief Executive Officer, President and Chairman of the Board of Directors (the “Board”) of OncoMed Pharmaceuticals, Inc. (the “Company”), began a personal leave of absence for medical reasons. Mr. Hastings will continue to be the Company’s Chief Executive Officer and Chairman of the Board during his leave of absence.

In addition, effective as of September 18, 2017, the Board created an Office of the President, whose members will provide overall leadership of the Company during Mr. Hastings’ leave of absence, and appointed John Lewicki, Ph.D., the Company’s Executive Vice President, Research and Development, and Sunil Patel, the Company’s Chief Financial Officer and Senior Vice President, Corporate Development and Finance, to serve as members of the Office of the President. In connection with his appointment as a member of the Office of the President, Mr. Patel was also promoted to Executive Vice President, Corporate Development and Finance.

In satisfaction of the disclosure required pursuant to Items 401(b) and 401(e) of Regulation S-K, the Company’s disclosures in its Definitive Proxy Statement on Schedule 14A, filed with the Securities and Exchange Commission on April 13, 2017, under the headings “Executive Officers—John A. Lewicki, Ph.D.” and “—Sunil Patel,” are incorporated by reference herein.

Neither Dr. Lewicki nor Mr. Patel has any family relationship required to be reported pursuant to Item 401(d) of Regulation S-K, and there are no relationships or transactions involving Dr. Lewicki or Mr. Patel required to be reported pursuant to Item 404(a) of Regulation S-K.

At the time of the filing of this Current Report on Form 8-K, the Board and its Compensation Committee had not made any determination regarding changes in compensatory plans or arrangements in connection with the matters described herein.

**Item 7.01. Regulation FD Disclosure.**

On September 19, 2017, the Company issued a press release (the “Press Release”) announcing the events disclosed under Item 5.02 of this Current Report on Form 8-K. The full text of the Press Release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

The information in Item 7.01 of this Current Report on Form 8-K (including Exhibit 99.1) shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing, regardless of any general incorporation language in any such filing, unless the Company expressly sets forth in such filing that such information is to be considered “filed” or incorporated by reference therein.

**Item 9.01. Financial Statements and Exhibits.****(d) Exhibits.**

<u>Exhibit No.</u>	<u>Description</u>
99.1	<a href="#">Press release of OncoMed Pharmaceuticals, Inc., issued September 19, 2017.</a>

---

**SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Date: September 19, 2017

ONCOMED PHARMACEUTICALS, INC.

By: /s/ Alicia J. Hager

Alicia J. Hager, J.D., Ph.D.

*Senior Vice President and General Counsel*



*For Immediate Release*

**OncoMed Chairman and CEO, Paul Hastings, to Take Medical Leave of Absence**

*Office of the President Established to Lead Company during Medical Leave*

**REDWOOD CITY, Calif. – September 19, 2017** – OncoMed Pharmaceuticals, Inc. (NASDAQ: OMED), a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics, today announced that its Chairman and Chief Executive Officer, Paul J. Hastings, has begun a personal leave of absence for medical reasons. Mr. Hastings will continue to be the Chief Executive Officer and Chairman of the Board of Directors during his leave of absence.

In Mr. Hastings' absence, OncoMed will be led by the Company's senior management team including the creation of an Office of the President consisting of Executive Vice President, Research and Development, John Lewicki, and Executive Vice President and Chief Financial Officer, Sunil Patel. In addition, OncoMed's Board of Directors has appointed a special committee of the Board, consisting of Jack Lasersohn, lead director of the Board, Perry Karsen, Deepa Pakianathan and Rick Winningham, to work closely with Dr. Lewicki and Mr. Patel during Mr. Hastings' medical leave.

Mr. Lasersohn commented, "We wish Paul a full and speedy recovery, and look forward to his return. In the meantime, we will continue to work closely with OncoMed's senior leadership team, dedicated employees, and our collaboration partner, Celgene, to advance OncoMed's science and novel therapeutics to patients."

**About OncoMed Pharmaceuticals**

OncoMed Pharmaceuticals is a clinical-stage biopharmaceutical company focused on discovering and developing novel anti-cancer therapeutics. OncoMed has internally discovered a broad pipeline of investigational drugs intended to address the fundamental biology driving cancer's growth, resistance, recurrence and metastasis. Navicixizumab (anti-DLL4/VEGF bispecific, OMP-305B83), rosmantuzumab (anti-RSPO3, OMP-131R10) and anti-TIGIT (OMP-313M32) are part of the company's strategic alliance with Celgene Corporation. OncoMed is independently developing GITRL-Fc (OMP-336B11), as well as continuing to pursue new drug discovery research. OncoMed is also evaluating potential partnering opportunities for Wnt pathway agents vantictumab (anti-Fzd, OMP-18R5) and ipafricept (Fzd8-Fc, OMP-54F28). For further information about OncoMed Pharmaceuticals, please see [www.oncomed.com](http://www.oncomed.com).

**Forward Looking Statements**

*To the extent that statements contained in this press release are not descriptions of historical facts regarding OncoMed Pharmaceuticals, they are forward-looking statements reflecting the current beliefs and expectations of management made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995, including, without limitation, OncoMed's ability to continue to execute on its business plan; OncoMed's ability to advance its research and development pipeline; and the ability of OncoMed's therapeutic candidates to improve outcomes for cancer patients. Such forward-looking statements involve substantial risks and uncertainties that could cause OncoMed's clinical development programs, future results, performance or achievements to differ significantly from those expressed or implied by the forward-looking statements. Such risks and uncertainties include, among others, the uncertainties inherent in the preclinical and clinical development process; OncoMed's ability to raise additional capital to support the development of its unpartnered programs; OncoMed's reliance on third parties to conduct certain preclinical studies and all of its clinical trials; and OncoMed's dependence on its*

---

*key executives. OncoMed undertakes no obligation to update or revise any forward-looking statements. For a further description of the risks and uncertainties that could cause actual results to differ from those expressed in these forward-looking statements, as well as risks relating to OncoMed's business in general, see OncoMed's Annual Report on Form 10-K filed with the U.S. Securities and Exchange Commission (SEC) on March 9, 2017, OncoMed's Quarterly Report on Form 10-Q filed with the SEC on August 2, 2017, and OncoMed's other current and periodic reports filed with the SEC.*

###

**Investor Relations Contact:**

Peter Rahmer  
Trout Group  
prahmer@troutgroup.com  
(646) 378-2973

Mike Zaroni  
Trout Group  
mzanoni@troutgroup.com  
(646) 378-2924